<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04690673</url>
  </required_header>
  <id_info>
    <org_study_id>FEPODPara2020-1</org_study_id>
    <nct_id>NCT04690673</nct_id>
  </id_info>
  <brief_title>Detection of Paracetamol Concentration in Blood-, Saline- and Urine Samples - a Validation Study for a Novel Technique</brief_title>
  <official_title>Detection of Paracetamol Concentration in Blood-, Saline- and Urine Samples With an Electrochemical Indicator in Healthy Volunteers - a Validation Study for a Novel Technique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johanna Kujala</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to assess whether a novel electrochemical tool is reliable in detecting&#xD;
      concentration of paracetamol in fingerprick- , saline-, urine-, and serum samples. We will&#xD;
      recruit 12 healthy volunteers aged 18-45. They will get 1 g oral paracetamol. Paracetamol&#xD;
      concentration will be detected from abovementioned samples at timely intervals for 24 hours,&#xD;
      analyzed with the novel electrochemical method and compared to gold standard&#xD;
      mass-spectrometry analysis.&#xD;
&#xD;
      Despite of extensive use, the mechanism of action of parasetamol is not completely&#xD;
      understood. The central serotonergic system may play a role. Endocannabinoid system is a&#xD;
      group of lipid mediators, that possibly is involved in mediating paracetamol effect to the&#xD;
      serotonergic system. Serum lipidomic assessment can be used to study endocannabinoid&#xD;
      metabolics. In this study we will try to assess changes in endocannabinoid system by looking&#xD;
      into serum lipidomics in order to understand the mechanism of action of paracetamol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Healthy volunteers</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Paracetamol concentration will be measured with the novel electrochemical method and mass-spectrometry.</measure>
    <time_frame>1 day</time_frame>
    <description>Paracetamol concentration will be measured with the novel electrochemical method and gold standard mass-spectrometry. Measurements are made from fingerprick-, venous blood-, saliva-, and urine samples. Measured concentrations are compared between matrixes and between laboratory analysis techniques.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in serum lipidomics after administration of paracetamol</measure>
    <time_frame>1 day</time_frame>
    <description>Mechanism of action of paracetamol is not exactly known. We will assess changes in serum lipidomic measurement after paracetamol administration in healthy individuals</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Drug Mechanism</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All healthy volunteers are in this group. They receive 1g paracetamol orally. Saline-, urine-, venous blood and fingerprick samples will be collected at timely intervals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>1 g oral paractamol</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Paracetamol concentration measurements and lipidomic assessment</intervention_name>
    <description>Paracetamol concentration is measured from saline-, urine-, venous blood- and fingerprick- samples at timely intervals. Also serum lipidomic assessment is performed from venous blood samples.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, no medication of any kind.&#xD;
&#xD;
          -  Age 18-45&#xD;
&#xD;
          -  BMI 18.5 - 30&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy, lactation.&#xD;
&#xD;
          -  prisoner&#xD;
&#xD;
          -  smoking&#xD;
&#xD;
          -  less than 3 months from prior blood donation or clinical pharmacological study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eija Kalso, Prof</last_name>
    <phone>+35847175885</phone>
    <email>eija.kalso@hus.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johanna Kujala</last_name>
    <phone>+358400780411</phone>
    <email>johanna.kujala@helsinki.fi</email>
  </overall_contact_backup>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 14, 2020</study_first_submitted>
  <study_first_submitted_qc>December 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>December 28, 2020</last_update_submitted>
  <last_update_submitted_qc>December 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Johanna Kujala</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>electrochemical</keyword>
  <keyword>Paracetamol</keyword>
  <keyword>Lipidomics</keyword>
  <keyword>Endocannabinoid system</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

